Evidence map›Paper›PMID 37614685›Full record

ArticleGeburtshilfe und Frauenheilkunde2023

Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre.

Sabine Matovina, Tobias Engler, Lea-Louise Volmer, Heike Müller, Eva-Maria Grischke, Annette Staebler, Markus Hahn, Sara Yvonne Brucker, Andreas Daniel Hartkopf

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Geburtshilfe und Frauenheilkunde, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sabine MatovinaDepartment of Women's Health, University of Tübingen, Tübingen, Germany.ORCID 0000-0001-5864-0244
Tobias EnglerDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
Lea-Louise VolmerDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
Heike MüllerDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
Eva-Maria GrischkeDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
Annette StaeblerInstitute of Pathology, Tübingen University Hospital, Tübingen, Germany.
Markus HahnDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
Sara Yvonne BruckerDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
Andreas Daniel HartkopfDepartment of Women's Health, University of Tübingen, Tübingen, Germany.
University of Tübingen · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biosimilarpathological complete responseprimary systemic therapytrastuzumab

Identifiers

PMID37614685
PMCPMC10442908
OpenAlexW4311159276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.